# Guardant360 Liquid CDx

Source: https://onco.cc/drugs/guardant360-liquid-cdx/  
OnCo record `guardant360-liquid-cdx` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A blood test from Guardant Health that reads tumour DNA in the bloodstream to find out whether certain targeted drugs for lung, breast or bowel cancer may work.

## Summary

Guardant360 Liquid CDx is a separate FDA premarket approval (P250027, approved 19 May 2026 on an application received 31 July 2025) from the older Guardant360 CDx (P200010). The approval order describes a qualitative sequencing test on circulating cell-free DNA covering 741 genes for small variants. The FDA companion diagnostic list carries seven claims for it: osimertinib (EGFR exon 19 deletions, L858R and T790M), amivantamab (EGFR exon 20 insertions), sotorasib (KRAS G12C) and trastuzumab deruxtecan (ERBB2/HER2 activating mutations) in non-small cell lung cancer; elacestrant and imlunestrant (ESR1 mutations) in breast cancer; and encorafenib with cetuximab (BRAF V600E) in colorectal cancer. The approval order states that a negative plasma result does not assure that the tumour is negative, and that patients negative for the listed biomarkers should be reflexed to tissue testing with an FDA-approved tissue test where feasible. For osimertinib it adds that efficacy has not been established in the T790M plasma-positive, tissue-negative or unknown population.

## Fields

- Kind: Test
- Status: approved
- Last checked: 2026-11-17
- Tags: test
- Brand: Guardant360 Liquid CDx
- Modality: Liquid biopsy companion diagnostic test (NGS, cfDNA)
- Mechanism: Hybrid-capture next-generation sequencing of cell-free DNA from plasma, collected in Streck Cell-Free DNA Blood Collection Tubes, detecting single nucleotide variants and small insertions and deletions in 741 genes, copy number amplifications in two genes, copy number loss in one gene and rearrangements in nine genes.
- Approvals: US 2026: Companion diagnostic (plasma) for osimertinib, amivantamab, sotorasib and trastuzumab deruxtecan in NSCLC, elacestrant and imlunestrant in breast cancer, and encorafenib in colorectal cancer; also tumour mutation profiling in solid tumours

## Notes

- What a result means: a detected alteration with a companion claim can make you eligible for the matched drug; a negative blood result does not rule the alteration out, and the approval order says tissue testing should follow where feasible.
- Read on 17 November 2026 from the openFDA PMA record for P250027 (approval order text, decision date 19 May 2026) and the FDA list of authorized companion diagnostic devices.

## Sources

- FDA PMA P250027: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250027
- openFDA PMA record P250027 (approval order text): https://api.fda.gov/device/pma.json?search=pma_number:P250027
- FDA: List of FDA-Authorized Companion Diagnostic Devices: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools

## Connected records

- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Elacestrant](https://onco.cc/drugs/elacestrant/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [Guardant360 CDx](https://onco.cc/drugs/guardant360-cdx/), [Imlunestrant](https://onco.cc/drugs/imlunestrant/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- biomarkers: [BRAF V600E (and V600K)](https://onco.cc/biomarkers/braf-v600e/), [EGFR exon 19 deletion](https://onco.cc/biomarkers/egfr-exon-19-deletion/), [EGFR exon 20 insertion](https://onco.cc/biomarkers/egfr-exon-20-insertion/), [EGFR L858R](https://onco.cc/biomarkers/egfr-l858r/), [EGFR T790M](https://onco.cc/biomarkers/egfr-t790m/), [ESR1 mutation (ligand-binding domain, usually in ctDNA)](https://onco.cc/biomarkers/esr1-mutation-ctdna/), [HER2 (ERBB2) activating mutation](https://onco.cc/biomarkers/her2-mutation/), [KRAS G12C](https://onco.cc/biomarkers/kras-g12c/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)
- targets: [BRAF](https://onco.cc/targets/braf/), [EGFR](https://onco.cc/targets/egfr/), [Estrogen receptor (ERα)](https://onco.cc/targets/estrogen-receptor/), [HER2](https://onco.cc/targets/her2/), [KRAS](https://onco.cc/targets/kras/)
- companies: [Guardant Health](https://onco.cc/companies/guardant-health/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Companion diagnostic](https://onco.cc/terms/companion-diagnostic-term/)

---
JSON: https://onco.cc/api/v1/entities/guardant360-liquid-cdx.json